8‐chloro‐adenosine activity in FLT3‐ITD acute myeloid leukemia-Reference-Cited by-同舟云学术

8‐chloro‐adenosine activity in FLT3‐ITD acute myeloid leukemia

Published:2019-02-15 Issue:9 Volume:234 Page:16295-16303
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Buettner Ralf¹,Nguyen Le Xuan Truong¹²^ORCID,Kumar Bijender¹,Morales Corey¹,Liu Chao³,Chen Lisa S.⁴,Pemovska Tea⁵,Synold Timothy W.⁶,Palmer Joycelynne⁷,Thompson Ryan¹,Li Ling¹,Hoang Dinh Hoa¹,Zhang Bin¹,Ghoda Lucy¹,Kowolik Claudia⁸,Kontro Mika⁹,Leitch Calum¹⁰,Wennerberg Krister⁵,Yu Xiaochun³,Chen Ching‐Cheng¹,Horne David⁸,Gandhi Varsha⁴,Pullarkat Vinod¹,Marcucci Guido¹,Rosen Steven T.¹

Affiliation:

1. Hematology Malignancies and Stem Cell Transplantation Institute, Gehr Family Center for Leukemia Research, City of Hope National Medical Center Duarte California

2. Department of Medical Biotechnology Biotechnology Center of Ho Chi Minh City Ho Chi Minh City Vietnam

3. Department of Cancer Genetics and Epigenetics City of Hope National Medical Center Duarte California

4. Department of Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas

5. Institute for Molecular Medicine Finland (FIMM), University of Helsinki Helsinki Finland

6. Department of Cancer Biology City of Hope National Medical Center Duarte California

7. Department of Information Sciences City of Hope National Medical Center Duarte California

8. Department of Molecular Medicine City of Hope National Medical Center Duarte California

9. Department of Hematology Helsinki University Hospital Comprehensive Cancer Center Helsinki Finland

10. Department of Clinical Science Center for Cancer Biomarkers CCBIO, University of Bergen Bergen Norway

Funder

Institut National Du Cancer

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.28294

Reference27 articles.

1. Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase

2. AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

3. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

4. Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

5. Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia;Leukemia;2024-04-20

2. A phase 1 trial of 8‐chloro‐adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics;Cancer;2023-10-28

3. Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress;Biomedicine & Pharmacotherapy;2023-01

4. A natural halogenated fluoride adenosine analog 5′‐fluorodeoxy adenosine induced anticolon cancer activity in vivo and in vitro;Environmental Toxicology;2022-07-22

5. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia;Current Opinion in Oncology;2022-07-16